Login to Your Account



Financings NEWS
Synlogic Inc. tucked a $29.4 million series A into its belt as it aims at the nexus of synthetic biology and the microbiome with the development of therapeutic microbes. Atlas Venture and New Enterprise Associates led the round, which will enable Cambridge, Mass.-based Synlogic to build out its microbial engineering platform and advance its preclinical pipeline through clinical proof of concept in several applications.
Cerecor Inc. closed the first tranche of a $32 million series B Monday with plans to advance CERC-301, its experimental adjunctive therapy for patients with severe major depressive disorder (MDD) who haven't adequately responded to other therapies and are considering suicide.

Restorgenex Corp., a public specialty biopharma built from four small biotechs on the shell of a defunct sports and entertainment promoter, has closed the fifth and final round of a $35.6 million private placement.

More Financings Headlines

Cast Your Vote

Has biotech’s bubble burst?: